| Grant number: | 15/16505-0 |
| Support Opportunities: | Research Grants - Young Investigators Grants |
| Start date: | March 01, 2016 |
| End date: | February 29, 2020 |
| Field of knowledge: | Biological Sciences - Immunology - Applied Immunology |
| Principal Investigator: | Ana Carolina Ramos Moreno |
| Grantee: | Ana Carolina Ramos Moreno |
| Host Institution: | Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil |
| City of the host institution: | São Paulo |
| Associated researchers: | Ana Paula Lepique ; Bruna Felício Milazzotto Maldonado Porchia Ribeiro ; Carina Buzzo de Lima ; Eliseu Frank de Araujo ; Luis Carlos de Souza Ferreira ; Luisa Lina Villa ; Vera Lucia Garcia Calich |
| Associated scholarship(s): | 17/25544-4 - Role of indoleamine 2,3 dioxygenase (IDO) in oncogenesis and immunosuppression of tumors associated with human papillomavirus (HPV),
BP.MS 16/00708-1 - Indoleamine 2,3 dioxygenase in the biology of papillomaviruses-induced tumors: neoadjuvant effects on the immunetherapy of tumors, BP.JP |
Abstract
In the last twelve years, solid evidence showed that the enzyme Indoleamine 2,3 dioxygenase-1 (IDO) is an important mediator of immune tolerance. While the similarities between IDO regulatory mechanisms and the molecular signature associated with cervical cancer and other tumors induced by human papillomavirus (HPV), the active role of IDO in these tumors has not been studied. Here, we will study two important fields that can support the success of an antitumor therapeutic approach. In the first phase, we will evaluate the link of the molecular mechanisms related to IDO and the profile of the immune response regarding HPV-associated tumors. Therefore, we will evaluate the cellular and molecular parameters using different in vitro and in vivo experimental models, as well as human biopsies. Moreover, knockout mice Ido (-/-), aryl hydrocarbon receptor (AHR) Ahr (-/-) and IL-6 (-/-) will be used for a robust assessment of the role of IDO in this tumor model. Once the parameters were established, the second stage of our research aims to develop a therapeutic approach based on the consortium of an IDO inhibitor (1-methyl-tryptophan) and an anti-oxidant (melatonin) with a specific anti-tumor vaccine formulation against HPV-induced tumors. We will evaluate the phenotype and function of specific T CD8+ cells, and other cell parameters, to establish the relevance of these events in a protective immunity activation achieved by the combination of the neoadjuvant therapy and antitumor vaccines. This research has innovative features, which could impact on the translation of basic science into clinical interventions, and promotes the nucleation of a new research frontline in the University of São Paulo. (AU)
| Articles published in Agência FAPESP Newsletter about the research grant: |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |